PRINCETON, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) today announced that Marc Rubin, M.D. has been elected by
the company's Board of Directors to serve as a director on Medarex's Board,
effective November 1, 2007.
Dr. Rubin is President and CEO of Titan Pharmaceutical, Inc., a
biopharmaceutical company publicly traded on the American Stock Exchange.
Prior to joining Titan in October 2007, he was Head of Global Research and
Development for Bayer Schering Pharma and a member of the Executive
Committee of Bayer Healthcare and the Board of Management of Bayer Schering
Pharma. Prior to his position at Bayer Schering Pharma, Dr. Rubin was a
Member of the Executive Board and President of Development for Schering AG,
as well as Chairman of Schering Berlin Inc. and President of Berlex
Pharmaceuticals, a division of Schering AG. His position included
responsibility for three Global Business Units. Before joining Schering AG,
Dr. Rubin held several positions of increasing responsibility at
GlaxoSmithKline, including oversight of the development, approval and
commercial strategy for numerous programs. Dr. Rubin completed his clinical
training in internal medicine at The Johns Hopkins Hospital and
subspecialty training in both oncology and infectious disease at the
National Institutes of Health. He received his M.D. from Cornell University
Medical College and did his undergraduate work at Cornell University.
"We are very pleased Marc is joining our Board of Directors," said
Howard H. Pien, President and CEO of Medarex. "He brings strong industry
experience to our Board which will complement the Board's leadership in
continuing to guide the company's future growth strategy and value
creation."
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 30 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase III clinical trials. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html /
CONTACT:
Investor Relations, Laura S. Choi,
+1-609-430-2880, Ext. 2216, or Jean Mantuano, Corporate
Communications (media), +1-609-430-2880, Ext. 2221, both of
Medarex
|
